Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melanie Thompson

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
AIDS (London, England)|May 4, 2021
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1Peter Ackerman, Melanie Thompson, Jean-Michel Molina, et al.
The Lancet. HIV|October 2, 2015
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trialJacob P Lalezari, Gulam H Latiff, Cynthia Brinson, et al.
Antiviral Therapy|July 30, 2019
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trialJose M Gatell, Javier O Morales-Ramirez, Debbie P Hagins, et al.
AIDS Research and Human Retroviruses|January 29, 2013
Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK StudyKathleen E Squires, Linda-Gail Bekker, Joseph J Eron, et al.
The Lancet. HIV|October 31, 2020
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE studyMax Lataillade, Jacob P Lalezari, Michael Kozal, et al.
The Journal of Infectious Diseases|February 28, 2002
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patientsConstance A Benson, Steven G Deeks, Scott C Brun, et al.
Lancet (London, England)|April 20, 2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trialsPaul E Sax, David Wohl, Michael T Yin, et al.
AIDS (London, England)|April 7, 2007
Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis, Jeffrey P Nadler, Daniel S Berger, et al.
Lancet (London, England)|November 20, 2022
Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case seriesJohn P Thornhill, Romain Palich, Jade Ghosn, et al.
The Lancet. HIV|August 7, 2025
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi processChloe Orkin, Amy Paterson, Alexa Elias, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
AIDS (London, England)|May 4, 2021
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1Peter Ackerman, Melanie Thompson, Jean-Michel Molina, et al.
The Lancet. HIV|October 2, 2015
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trialJacob P Lalezari, Gulam H Latiff, Cynthia Brinson, et al.
Antiviral Therapy|July 30, 2019
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trialJose M Gatell, Javier O Morales-Ramirez, Debbie P Hagins, et al.
AIDS Research and Human Retroviruses|January 29, 2013
Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK StudyKathleen E Squires, Linda-Gail Bekker, Joseph J Eron, et al.
The Lancet. HIV|October 31, 2020
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE studyMax Lataillade, Jacob P Lalezari, Michael Kozal, et al.
The Journal of Infectious Diseases|February 28, 2002
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patientsConstance A Benson, Steven G Deeks, Scott C Brun, et al.
Lancet (London, England)|April 20, 2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trialsPaul E Sax, David Wohl, Michael T Yin, et al.
AIDS (London, England)|April 7, 2007
Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis, Jeffrey P Nadler, Daniel S Berger, et al.
Lancet (London, England)|November 20, 2022
Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case seriesJohn P Thornhill, Romain Palich, Jade Ghosn, et al.
The Lancet. HIV|August 7, 2025
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi processChloe Orkin, Amy Paterson, Alexa Elias, et al.
Pageof 6